CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview

Mohamad Mohty, Remy Dulery, Jordan Gauthier, Florent Malard, Eolia Brissot, Mahmoud Aljurf, Ali Bazarbachi, Christian Chabanon, Mohamed A. Kharfan-Dabaja, Bipin N. Savani, He Huang, Saad S. Kenderian, Miguel Angel Perales, Ibrahim Yakoub-Agha, Arnon Nagler

Research output: Contribution to journalReview articlepeer-review

Abstract

The goal of this review is to firstly address the concept of chimeric antigen receptor T-cell (CAR T-cell) therapy and where it fits in the evolving landscape of the management of patients with refractory/relapsed diffuse large B-cell lymphoma. The recognition of the indications for CAR T-cell therapy for patients with aggressive B-cell lymphoma will be discussed, including a review of the algorithms and selection criteria for CAR T-cell therapy and finally, the role of bridging therapy and the timing of CAR T-cell therapy in augmenting chances of a successful outcome.

Original languageEnglish
Pages (from-to)1525-1532
Number of pages8
JournalBone Marrow Transplantation
Volume55
Issue number8
DOIs
StatePublished - 1 Aug 2020

Fingerprint

Dive into the research topics of 'CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview'. Together they form a unique fingerprint.

Cite this